- Current report filing (8-K)
November 10 2008 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (date of earliest event reported): November 10, 2008
Cougar
Biotechnology, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other jurisdiction of incorporation)
001-33871
|
|
20-2903204
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
10990
Wilshire Blvd, Suite 1200
Los
Angeles, CA 90024
|
(Address of principal executive offices) (Zip Code)
|
(310) 943-8040
(Registrant’s telephone number, including area
code)
N/A
(Former name or former address, if changed
since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
2.02 Results of Operations and Financial Condition.
On November 10, 2008, Cougar Biotechnology, Inc. (the “Company”) issued
a press release announcing its financial results for the three and nine
months ended September 30, 2008. A copy of this press release is
furnished herewith as Exhibit 99.1. Pursuant to the rules and
regulations of the Securities and Exchange Commission, such exhibit and
the information set forth therein and in this Item 2.02 have been
furnished and shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to liability under that section nor shall they be
deemed incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing regardless of any general
incorporation language.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
|
|
Description
|
99.1
|
|
Press release dated November 10, 2008.
|
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
COUGAR BIOTECHNOLOGY, INC.
|
|
|
|
|
|
|
|
|
Date:
|
November 10, 2008
|
|
By:
|
/s/ Charles R. Eyler
|
|
|
|
Charles R. Eyler
|
|
|
|
Treasurer and Sr. Vice President, Finance
|
INDEX TO EXHIBITS FILED WITH THIS REPORT
Exhibit No.
|
|
Description
|
99.1
|
|
Press release dated November 10, 2008
|
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cougar Biotechnology (MM) (NASDAQ:CGRB)
Historical Stock Chart
From Jul 2023 to Jul 2024